Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Hepion Pharmaceuticals stock | $1.7
Learn how to easily invest in Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals, Inc is a biotechnology business based in the US. Hepion Pharmaceuticals shares (HEPA) are listed on the NASDAQ and all prices are listed in US Dollars. Hepion Pharmaceuticals employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Hepion Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – HEPA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Hepion Pharmaceuticals stock price (NASDAQ: HEPA)Use our graph to track the performance of HEPA stocks over time.
Hepion Pharmaceuticals shares at a glance
|Latest market close||$1.70|
|52-week range||$1.45 - $4.83|
|50-day moving average||$1.94|
|200-day moving average||$1.97|
|Wall St. target price||$6.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-50.58|
Buy Hepion Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Hepion Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Hepion Pharmaceuticals price performance over time
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||-19.05%|
|3 months (2021-04-30)||-1.73%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
Hepion Pharmaceuticals financials
|Gross profit TTM||$0|
|Return on assets TTM||-18.7%|
|Return on equity TTM||-32.54%|
|Market capitalisation||$118.9 million|
TTM: trailing 12 months
Shorting Hepion Pharmaceuticals shares
There are currently 2.4 million Hepion Pharmaceuticals shares held short by investors – that's known as Hepion Pharmaceuticals's "short interest". This figure is 65.6% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting Hepion Pharmaceuticals shares can be evaluated.
Hepion Pharmaceuticals's "short interest ratio" (SIR)
Hepion Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Hepion Pharmaceuticals shares currently shorted divided by the average quantity of Hepion Pharmaceuticals shares traded daily (recently around 2.5 million). Hepion Pharmaceuticals's SIR currently stands at 0.94. In other words for every 100,000 Hepion Pharmaceuticals shares traded daily on the market, roughly 940 shares are currently held short.
However Hepion Pharmaceuticals's short interest can also be evaluated against the total number of Hepion Pharmaceuticals shares, or, against the total number of tradable Hepion Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hepion Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Hepion Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0354% of the tradable shares (for every 100,000 tradable Hepion Pharmaceuticals shares, roughly 35 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hepion Pharmaceuticals.
Find out more about how you can short Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals share dividends
We're not expecting Hepion Pharmaceuticals to pay a dividend over the next 12 months.
Have Hepion Pharmaceuticals's shares ever split?
Hepion Pharmaceuticals's shares were split on a 1:70 basis on 2 June 2019. So if you had owned 70 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Hepion Pharmaceuticals shares – just the quantity. However, indirectly, the new 6900% higher share price could have impacted the market appetite for Hepion Pharmaceuticals shares which in turn could have impacted Hepion Pharmaceuticals's share price.
Hepion Pharmaceuticals share price volatility
Over the last 12 months, Hepion Pharmaceuticals's shares have ranged in value from as little as $1.45 up to $4.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hepion Pharmaceuticals's is 1.161. This would suggest that Hepion Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Hepion Pharmaceuticals overview
Hepion Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc.
Stocks similar to Hepion Pharmaceuticals
Hepion Pharmaceuticals in the news
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
First Week of March 2022 Options Trading For Hepion Pharmaceuticals
Frequently asked questionsWhat percentage of Hepion Pharmaceuticals is owned by insiders or institutions?
Currently 0.145% of Hepion Pharmaceuticals shares are held by insiders and 24.091% by institutions. How many people work for Hepion Pharmaceuticals?
Latest data suggests 13 work at Hepion Pharmaceuticals. When does the fiscal year end for Hepion Pharmaceuticals?
Hepion Pharmaceuticals's fiscal year ends in December. Where is Hepion Pharmaceuticals based?
Hepion Pharmaceuticals's address is: 399 Thornall Street, Edison, NJ, United States, 08837 What is Hepion Pharmaceuticals's ISIN number?
Hepion Pharmaceuticals's international securities identification number is: US4268971045 What is Hepion Pharmaceuticals's CUSIP number?
Hepion Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 21234W103
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert